Overview

Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This is single arm a Phase 2, single center study of talimogene laherparepvec (TVEC) to treat low risk cutaneous squamous cell carcinomas (cSCC).
Phase:
Phase 2
Details
Lead Sponsor:
University of Arizona
Collaborator:
Amgen
Treatments:
Talimogene laherparepvec